Geopolitical Tensions and Supply Chain Fragmentation: How Site-Neutral Manufacturing Addresses the Three-Block Reality
Day 2 Global Pharma Outlook Stage
07/10/2026 13:45 - 14:10pm
Contributors
Michael Kraich : Vice President of Global Project & Product Management BioXcellence - Boehringer Ingelheim Biopharmaceuticals
As biologics complexity grows, driven by new modalities, demand volatility, and geopolitical pressures, tech transfer speed and execution quality have become critical bottlenecks. This session examines how AI-driven manufacturing, rapid site-to-site transfers (6-12 months to first GMP run), and globally integrated networks address the structural challenges of supply chain resilience, regulatory acceleration, and CDMO selectivity.
Drawing on lessons from 150+ successful tech transfers across 49 commercialised products, Boehringer Ingelheim explores the economic trade-offs between flexibility and localisation, and why execution capability, not just capacity, now determines competitive advantage in biologics manufacturing.
- Supply Chain Resilience in a Fragmented World: Balancing Regional Capacity with Global Integration
- Tech Transfer as the Hidden Constraint: Accelerating from 18-24 Months to 6-12 Months
- Digital Manufacturing Beyond the Hype: Closing the Execution Gap in AI-Driven Biologics Production
- Execution Quality as the New CDMO Differentiator: Why Not All Capacity Is Created Equal.